Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable

被引：0
|
作者：
Yuen, Lisa [1 ,2 ]
Gogakos, Tasos [1 ,2 ,3 ]
Boiocchi, Leonardo [4 ]
Hobbs, Gabriela [2 ,5 ]
Hasserjian, Robert [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[5] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年
关键词：
D O I：
10.1002/ajh.27530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    Tefferi, A.
    Saeed, L.
    Hanson, C. A.
    Ketterling, R. P.
    Pardanani, A.
    Gangat, N.
    LEUKEMIA, 2017, 31 (12) : 2851 - 2852
  • [42] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    Mesa, R. A.
    Camoriano, J. K.
    Geyer, S. M.
    Wu, W.
    Kaufmann, S. H.
    Rivera, C. E.
    Erlichman, C.
    Wright, J.
    Pardanani, A.
    Lasho, T.
    Finke, C.
    Li, C. Y.
    Tefferi, A.
    LEUKEMIA, 2007, 21 (09) : 1964 - 1970
  • [43] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    R A Mesa
    J K Camoriano
    S M Geyer
    W Wu
    S H Kaufmann
    C E Rivera
    C Erlichman
    J Wright
    A Pardanani
    T Lasho
    C Finke
    C Y Li
    A Tefferi
    Leukemia, 2007, 21 : 1964 - 1970
  • [44] Incidence and Characteristics of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis in Thailand: A 5-Year Retrospective Study
    Khuhapinant, Archrob
    Lertchaisataporn, Kamoltip
    Phikulsod, Ployploen
    Siritanaratkul, Noppadol
    BLOOD, 2014, 124 (21)
  • [45] Primary Myelofibrosis Displays an Inflammation-Associated Gene Profile Distinct from Polycythemia Vera and Essential Thrombocythemia
    Pozdnyakova, Olga
    Aster, Jon C.
    Kuo, Frank
    Brown, Ronald
    Baltay, Michele
    Hasserjian, Robert P.
    LABORATORY INVESTIGATION, 2016, 96 : 370A - 371A
  • [46] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Newberry, Kate J.
    Manshouri, Taghi
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
  • [47] Primary Myelofibrosis Displays an Inflammation-Associated Gene Profile Distinct from Polycythemia Vera and Essential Thrombocythemia
    Pozdnyakova, Olga
    Aster, Jon C.
    Kuo, Frank
    Brown, Ronald
    Baltay, Michele
    Hasserjian, Robert P.
    MODERN PATHOLOGY, 2016, 29 : 370A - 371A
  • [48] Basophilia Predicts Poorer Outcomes in BCR-ABL1-Negative Myeloproliferative Neoplasms
    Yuen, Lisa
    Gogakos, Tasos
    Boiocchi, Leonardo
    Hobbs, Gabriela
    Hasserjian, Robert
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1048 - 1049
  • [49] Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval G.
    Pemmaraju, Naveen
    Newberry, Kate J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [50] TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    A Pardanani
    K-H Lim
    O Abdel-Wahab
    T L Lasho
    J Patel
    N Gangat
    C M Finke
    S Schwager
    A Mullally
    C-Y Li
    C A Hanson
    R Mesa
    O Bernard
    F Delhommeau
    W Vainchenker
    D G Gilliland
    R L Levine
    Leukemia, 2009, 23 : 905 - 911
12345